These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 7536207)
1. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly. Giustina A; Bresciani E; Bussi AR; Bollati A; Bonfanti C; Bugari G; Chiesa L; Giustina G J Clin Endocrinol Metab; 1995 Apr; 80(4):1333-40. PubMed ID: 7536207 [TBL] [Abstract][Full Text] [Related]
2. Galanin decreases circulating growth hormone levels in acromegaly. Giustina A; Bodini C; Doga M; Schettino M; Pizzocolo G; Giustina G J Clin Endocrinol Metab; 1992 Jun; 74(6):1296-300. PubMed ID: 1375598 [TBL] [Abstract][Full Text] [Related]
3. Effects of metoclopramide on the paradoxical growth hormone response to galanin in acromegaly. Giustina A; Doga M; Bodini C; Bossoni S; Bresciani E; Bussi AR Endocr Res; 1993 Dec; 19(4):303-15. PubMed ID: 7508379 [TBL] [Abstract][Full Text] [Related]
4. Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly. Giustina A; Doga M; Bussi AR; Licini M; Schettino M Acta Endocrinol (Copenh); 1993 Feb; 128(2):131-5. PubMed ID: 7680832 [TBL] [Abstract][Full Text] [Related]
5. Effect of galanin on the growth hormone response to growth hormone-releasing hormone in acromegaly. Giustina A; Schettino M; Bodini C; Doga M; Licini M; Giustina G Metabolism; 1992 Dec; 41(12):1291-4. PubMed ID: 1281259 [TBL] [Abstract][Full Text] [Related]
6. Biochemical evaluation of patients with active acromegaly and type 2 diabetes mellitus: efficacy and safety of the galanin test. Mazziotti G; Bonadonna S; Doga M; Patelli I; Gazzaruso C; Solerte SB; De Menis E; Giustina A Neuroendocrinology; 2008; 88(4):299-304. PubMed ID: 18617732 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly. Losa M; Oeckler R; Schopohl J; Müller OA; Alba-Lopez J; von Werder K J Neurosurg; 1989 Apr; 70(4):561-7. PubMed ID: 2647918 [TBL] [Abstract][Full Text] [Related]
8. [Reevaluation of the I-dopa test in acromegaly: anatomo-clinical and prognostic correlations]. De Marinis L; Mancini A; Zuppi P; Fiumara C; Iacona T; Conte G; Fabrizi ML; Valle D; Anile C; Maira G Minerva Chir; 1993 Nov; 48(21-22):1337-40. PubMed ID: 8152567 [TBL] [Abstract][Full Text] [Related]
9. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly. Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226 [TBL] [Abstract][Full Text] [Related]
10. Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly. Losa M; Schopohl J; König A; Müller OA; von Werder K J Clin Endocrinol Metab; 1986 Aug; 63(2):475-80. PubMed ID: 3088026 [TBL] [Abstract][Full Text] [Related]
11. Lack of desensitization of adenomatous somatotrophs to growth-hormone releasing hormone in acromegaly. Spada A; Elahi FR; Arosio M; Sartorio A; Guglielmino L; Vallar L; Faglia G J Clin Endocrinol Metab; 1987 Mar; 64(3):585-91. PubMed ID: 3102543 [TBL] [Abstract][Full Text] [Related]
12. Growth hormone secretory response to intravenous galanin infusion in acromegalic patients. Cuerda C; Lucas T; Silvestre RA; Bretón I; García P; Marco J; Barceló B Exp Clin Endocrinol Diabetes; 1998; 106(1):68-73. PubMed ID: 9516063 [TBL] [Abstract][Full Text] [Related]
13. The GH-releasing hormone (GHRH) test in acromegaly before and after adenomectomy. Giusti M; Lomeo A; Monachesi M; Mazzocchi G; Attanasio R; Sessarego P; Mignone D; Del Monte P; Giordano G J Endocrinol Invest; 1987 Apr; 10(2):143-51. PubMed ID: 3108356 [TBL] [Abstract][Full Text] [Related]
14. Growth hormone-releasing hormone infusion in patients with active acromegaly. Losa M; Chiodini PG; Liuzzi A; König A; Müller OA; Schopohl J; von Werder K J Clin Endocrinol Metab; 1986 Jul; 63(1):88-93. PubMed ID: 3086362 [TBL] [Abstract][Full Text] [Related]
15. Octreotide as primary therapy for acromegaly. Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397 [TBL] [Abstract][Full Text] [Related]
16. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly. Kelijman M; Williams TC; Downs TR; Frohman LA J Clin Endocrinol Metab; 1988 Nov; 67(5):958-63. PubMed ID: 2903171 [TBL] [Abstract][Full Text] [Related]
18. Effects of metoclopramide on the growth hormone response to galanin in normal man. Giustina A; Bussi AR; Doga M; Licini M; Schettino M; Wehrenberg WB Horm Metab Res; 1993 Sep; 25(9):489-92. PubMed ID: 7693566 [TBL] [Abstract][Full Text] [Related]
19. Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly. Ishibashi M; Yamaji T J Clin Endocrinol Metab; 1978 Dec; 47(6):1251-6. PubMed ID: 122426 [TBL] [Abstract][Full Text] [Related]
20. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses. Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]